| Literature DB >> 9427607 |
K D Bunting1, M Y Sangster, J N Ihle, B P Sorrentino.
Abstract
Janus kinase-3 (JAK3) deficiency has recently been identified as a cause of severe combined immunodeficiency (SCID) in humans. We used a mouse model of Jak3-deficient SCID to test a gene therapy approach for treatment of this disease. Transfer of a Jak3 retroviral vector to repopulating hematopoietic stem cells resulted in increased numbers of T and B lymphocytes, reversal of hypogammaglobulinemia, restoration of T-cell activation upon stimulation with mitogens, and development of an antigen-specific immune response after immunization. Analysis for vector copy number in lymphoid and myeloid populations showed a large in vivo selective advantage for Jak3-expressing lymphoid cells. These results show that gene replacement is a feasible treatment strategy for this disease and that naturally occurring in vivo selection of corrected cells is an important advantage of this approach.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9427607 DOI: 10.1038/nm0198-058
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440